BridgeBio Pharma Inc [BBIO] stock prices are down -0.91% to $38.22 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BBIO shares have gain 6.49% over the last week, with a monthly amount glided 12.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BridgeBio Pharma Inc [NASDAQ: BBIO] stock has seen the most recent analyst activity on March 31, 2025, when Redburn Atlantic initiated its Buy rating and assigned the stock a price target of $50. On October 03, 2024, Oppenheimer initiated with a Perform rating. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $46 on September 04, 2024. BMO Capital Markets started tracking with a Market Perform rating for this stock on January 31, 2024, and assigned it a price target of $37. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $58 on this stock.
The stock price of BridgeBio Pharma Inc [BBIO] has been fluctuating between $21.62 and $39.54 over the past year. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $38.22 at the most recent close of the market. An investor can expect a potential return of 17.74% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
The BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 127.42M for trailing twelve months, representing a drop of -44.76%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -5.48%, Pretax Profit Margin comes in at -5.29%, and Net Profit Margin reading is -5.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is 0.49 and Total Capital is -0.96. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.74 points at the first support level, and at 37.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.71, and for the 2nd resistance point, it is at 39.21.
Ratios To Look Out For
It’s worth pointing out that BridgeBio Pharma Inc [NASDAQ:BBIO]’s Current Ratio is 4.57. In addition, the Quick Ratio stands at 4.54 and the Cash Ratio stands at 3.55. Considering the valuation of this stock, the price to sales ratio is 56.96.
Transactions by insiders
Recent insider trading involved Lo Andrew, Director, that happened on May 02 ’25 when 100000.0 shares were purchased. Chief Executive Officer, Kumar Neil completed a deal on Apr 22 ’25 to sell 75000.0 shares. Meanwhile, Director Ellis Andrea sold 10000.0 shares on Apr 14 ’25.
